Фармсинтез LIFE

Фармсинтез Financial Ratios 2007-2026 | LIFE

Annual Financial Ratios Фармсинтез

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Price Earnings Ratio, P/E	-6.09	-2.42	-3.93	-0.69	27.1	-1.31	-2.79	-4.62	-8.85	-12.45	-15.04	435.18	367.11	213.28	1410.81	177.55
Price Sales Ratio, P/S	3.33	3.85	5.55	4.29	5.75	4.58	3.79	4.95	4.8	7.48	3.08	14.79	25.42	13.11	16.64	17.36
Price To Book Ratio, P/B	10.43	4.89	2.03	0.3	0.33	1.88	0.54	0.77	0.78	1.06	1.18	7.37	24.18	11.08	11.27	11.35
Price Earnings To Growth Ratio, PEG	0.09	-0.07	0.06	0.0	-0.26	-0.02	-0.02	-0.07	-2.02	-0.16	0.01	-16.4	-8.65	0.39	-16.06	-
Operating Cash Flow Per Share	-0.01	-0.21	-0.77	-0.32	-0.05	-0.5	-3.81	-1.34	-5.89	-3.27	-1.65	0.18	-	-	-	-
Free Cash Flow Per Share	-0.02	-0.21	-0.81	-0.37	-0.12	-0.59	-4.03	-1.44	-6.46	-4.43	-2.67	-0.1	-0.05	-0.04	-0.03	-
Cash Per Share	0.03	0.05	0.03	0.25	0.05	1.37	3.02	2.03	1.25	5.16	1.08	1.15	1.55	0.18	0.03	0.05
Payout Ratio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend Yield	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.17	0.21	0.45	0.27	0.38	0.97	1.8	1.92	5.32	2.55	2.01	3.67	1.13	1.49	1.37	1.21
Quick Ratio	0.13	0.17	0.39	0.16	0.18	0.79	1.62	1.61	4.62	2.37	1.67	3.3	1.0	0.85	0.78	0.7
Cash Ratio	0.01	0.02	0.01	0.04	0.0	0.29	0.39	0.01	0.5	1.16	0.37	0.02	0.02	0.21	0.03	0.06
Days Of Sales Outstanding, DSO	-	-	-	-	-	223.54	326.27	466.14	-	232.19	208.62	-	-	-	-	-
Days Of Inventory Outstanding, DIO	51.23	47.63	119.91	213.33	393.03	181.58	230.38	488.98	343.85	185.71	159.18	80.42	165.58	157.1	247.77	219.47
Days Of Payables Outstanding, DPO	218.15	185.98	306.44	335.64	753.34	391.6	6610.55	389.91	284.97	124.61	323.0	-	138.24	173.17	307.87	384.67
Operating Cycle	51.23	47.63	119.91	213.33	393.03	405.12	556.64	955.12	343.85	417.9	367.79	80.42	165.58	157.1	247.77	219.47
Cash Conversion Cycle	-166.92	-138.34	-186.53	-122.32	-360.31	13.51	-6053.91	565.21	58.89	293.29	44.8	80.42	27.35	-16.07	-60.09	-165.2
Gross Profit Margin	0.21	0.37	0.43	0.1	0.11	0.43	0.59	0.49	0.56	0.37	0.45	0.28	0.38	0.32	0.44	0.46
Operating Profit Margin	-0.44	-0.39	-0.11	-6.94	0.24	-3.98	-0.93	-1.81	-0.55	-0.73	-0.68	0.01	0.15	0.07	0.12	0.19
Pretax Profit Margin	-0.55	-1.67	-1.42	-6.97	0.01	-3.93	-1.43	-1.2	-0.53	-0.63	-0.23	0.07	0.1	0.03	0.03	0.14
Net Profit Margin	-0.55	-1.59	-1.41	-6.22	0.21	-3.49	-1.36	-1.07	-0.54	-0.6	-0.2	0.03	0.07	0.06	0.01	0.1
Effective Tax Rate	0.01	0.05	0.0	-0.11	-32.04	0.03	0.04	0.11	-0.03	0.04	0.12	0.5	0.29	-1.26	0.62	0.32
Return On Assets, ROA	-0.16	-0.49	-0.26	-0.31	0.01	-0.75	-0.15	-0.12	-0.08	-0.07	-0.06	0.01	0.02	0.04	0.01	0.04
Return On Equity, ROE	-1.71	-2.02	-0.52	-0.43	0.01	-1.43	-0.2	-0.17	-0.09	-0.09	-0.08	0.02	0.07	0.05	0.01	0.06
Return On Capital Employed, ROCE	-1.03	-0.39	-0.04	-0.46	0.01	-1.29	-0.12	-0.28	-0.09	-0.1	-0.26	0.0	0.14	0.06	0.08	0.12
Net Income Per Ebt	0.99	0.95	1.0	0.89	33.04	0.89	0.95	0.89	1.03	0.96	0.88	0.5	0.71	2.26	0.38	0.68
Ebt Per Ebit	1.25	4.34	12.73	1.0	0.03	0.99	1.53	0.66	0.95	0.85	0.34	9.33	0.64	0.38	0.27	0.76
Ebit Per Revenue	-0.44	-0.39	-0.11	-6.94	0.24	-3.98	-0.93	-1.81	-0.55	-0.73	-0.68	0.01	0.15	0.07	0.12	0.19
Debt Ratio	0.56	0.5	0.3	0.03	0.0	0.07	0.04	0.1	0.01	0.16	0.05	0.01	0.0	0.06	0.06	0.02
Debt Equity Ratio	6.16	2.05	0.61	0.04	0.0	0.13	0.05	0.14	0.01	0.2	0.06	0.01	0.0	0.08	0.09	0.03
Long Term Debt To Capitalization	0.12	0.2	0.01	0.03	-	0.03	-	-	-	-	-	-	-	-	-	-
Total Debt To Capitalization	0.86	0.67	0.38	0.04	0.0	0.12	0.05	0.12	0.01	0.17	0.06	0.01	0.0	0.07	0.09	0.03
Interest Coverage	-4.05	-4.65	-1.4	-	11.49	-634.17	-194.6	-279.15	-98.25	-96.71	-37.61	1	33.06	5.4	12.82	232.68
Cash Flow To Debt Ratio	-0.0	-0.09	-0.37	-0.59	-0.67	-0.59	-2.58	-0.69	-24.39	-1.02	-2.75	8.93	-	-	-	-
Company Equity Multiplier	11.05	4.13	2.02	1.4	1.33	1.92	1.33	1.35	1.1	1.26	1.27	1.23	3.1	1.39	1.45	1.43
Receivables Turnover	-	-	-	-	-	1.63	1.12	0.78	-	1.57	1.75	-	-	-	-	-
Payables Turnover	1.67	1.96	1.19	1.09	0.48	0.93	0.06	0.94	1.28	2.93	1.13	-	2.64	2.11	1.19	0.95
Inventory Turn Over	7.12	7.66	3.04	1.71	0.93	2.01	1.58	0.75	1.06	1.97	2.29	4.54	2.2	2.32	1.47	1.66
Fixed Asset Turnover	1.1	1.34	1.06	0.93	0.85	1.76	1.64	0.76	0.81	0.6	0.79	8.58	1.43	1.17	0.87	0.77
Asset Turnover	0.28	0.31	0.18	0.05	0.04	0.21	0.11	0.12	0.15	0.11	0.3	0.41	0.31	0.61	0.47	0.46
Operating Cash Flow Sales Ratio	-0.01	-0.14	-0.63	-0.33	-0.05	-0.19	-0.87	-0.61	-2.23	-1.44	-0.44	0.13	-	-	-	-
Free Cash Flow Operating Cash Flow Ratio	2.04	1.0	1.04	1.15	2.25	1.18	1.06	1.07	1.1	1.35	1.62	-0.54	-	-	-	-
Cash Flow Coverage Ratios	-0.0	-0.09	-0.37	-0.59	-0.67	-0.59	-2.58	-0.69	-24.39	-1.02	-2.75	8.93	-	-	-	-
Short Term Coverage Ratios	-0.0	-0.1	-0.38	-0.32	-0.67	-0.78	-2.58	-0.71	-35.45	-1.04	-2.96	8.93	-	-	-	-
Capital Expenditure Coverage Ratio	-0.97	-224.71	-24.04	-6.66	-0.8	-5.67	-17.2	-13.95	-10.36	-2.82	-1.61	0.65	-	-	-	-
Dividend Paid And Capex Coverage Ratio	-0.97	-224.71	-24.04	-6.66	-0.8	-5.67	-17.2	-13.95	-10.36	-2.82	-1.61	0.65	-	-	-	-
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Price To Free Cash Flows Ratio, P/FCF	-185.11	-26.82	-8.5	-11.24	-46.49	-20.49	-4.1	-7.5	-1.97	-3.84	-4.35	-212.02	-503.78	-599.39	-791.95	-
Price To Operating Cash Flows Ratio, P/OCF	-376.79	-26.93	-8.86	-12.93	-104.6	-24.1	-4.34	-8.04	-2.16	-5.19	-7.05	113.77	-	-	-	-
Price Cash Flow Ratio, P/CF	-376.79	-26.93	-8.86	-12.93	-104.6	-24.1	-4.34	-8.04	-2.16	-5.19	-7.05	113.77	-	-	-	-
Enterprise Value Multiple, EV	-14.29	-3.68	-13.43	-7.03	-7.69	-3.2	-3.84	-5.29	-10.82	-14.09	-26.44	196.63	249.53	323.42	416.32	120.47
Price Fair Value, P/FV	10.43	4.89	2.03	0.3	0.33	1.88	0.54	0.77	0.78	1.06	1.18	7.37	24.18	11.08	11.27	11.35

All numbers in RUB currency

Quarterly Financial Ratios Фармсинтез

	2023-Q2	2022-Q4	2022-Q2	2021-Q4	2021-Q2	2020-Q4	2020-Q2	2019-Q4	2019-Q2	2018-Q4	2018-Q2	2017-Q4	2017-Q2	2016-Q4	2016-Q2	2015-Q4	2015-Q2	2014-Q4	2014-Q2	2013-Q4	2013-Q2	2012-Q4	2011-Q4	2011-Q2	2010-Q4	2010-Q2	2009-Q4	2009-Q2	2008-Q4	2008-Q2
Price Earnings Ratio, P/E	-3.49	-2.21	-4.52	-0.948	-1.85	-1.24	-4.56	-0.17	-10.3	-13.1	-1.43	-0.741	-0.612	-0.543	1.19	-5.72	-1.69	-4.43	-4.82	3.38	-2.94	-7.52	218	250	184	189	107	107	88.8	705
Price Sales Ratio, P/S	13.2	7.22	5.86	7.8	8.41	8.99	13.8	12.8	8.46	6.71	21.1	7.92	10.8	5.35	12.6	13.2	7.75	9.6	10.5	8.08	38.1	6.16	29.6	34	50.8	52.5	26.2	26.2	34.7	33.3
Price To Book Ratio, P/B	3.59	10.2	3.54	4.89	2.5	2.03	1.41	0.883	0.368	0.473	1.63	1.71	1.44	0.545	0.952	0.771	0.961	0.783	1.07	1.22	1.2	1.18	7.37	12.6	24.2	25.8	11.1	11.2	-	11.3
Price Earnings To Growth Ratio, PEG	-0.279	-0.019	0.053	-0.012	0.047	-0.004	0.048	-0.0	-0.483	0.143	0.021	0.039	0.018	0.002	-0.001	0.077	-0.01	-	0.031	-0.019	-0.009	-	-	-9.44	-	-4.47	-	0.195	-	-8.03
Operating Cash Flow Per Share	-0.001	0.0	-0.0	-0.118	-0.09	-0.469	-0.308	-0.082	-0.144	-0.0	-0.0	0.0	-0.0	-0.003	0.0	-0.001	-0.0	-0.003	-0.003	-1.43	-1.91	-1.25	0.089	0.089	-	-	-	-	-	-
Free Cash Flow Per Share	-0.001	0.0	-0.0	-0.119	-0.091	-0.489	-0.32	-0.132	-0.144	-0.0	-0.0	0.0	-0.0	-0.003	0.0	-0.001	-0.0	-0.003	-0.003	-1.94	-2.58	-1.69	-0.048	-0.048	-0.023	-0.023	-0.02	-0.02	-0.008	-0.015
Cash Per Share	0.848	0.145	0.003	0.045	0.04	0.035	0.06	0.231	0.043	0.016	0.837	1.51	0.297	3.02	0.818	2.27	1.49	1.25	2.99	4.52	9.62	1.08	1.15	1.35	1.55	0.812	0.18	0.106	-	0.04
Payout Ratio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend Yield	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.542	0.169	0.25	0.208	0.303	0.454	0.516	0.505	0.266	0.578	0.695	0.974	1.16	1.8	1.16	1.92	3.74	5.32	7.35	2.55	2.9	2.01	3.67	1.7	1.13	1.18	1.49	1.43	-	1.29
Quick Ratio	0.46	0.133	0.209	0.171	0.233	0.386	0.423	0.421	0.112	0.385	0.536	0.793	0.982	1.62	0.982	1.61	3.02	4.62	6.54	2.37	2.72	1.67	3.3	1.52	0.999	0.978	0.854	0.817	-	0.744
Cash Ratio	0.248	0.008	0.003	0.015	0.011	0.01	0.018	0.073	0.0	0.005	0.169	0.286	0.006	0.386	0.006	0.01	0.041	0.501	2.5	1.16	1.89	0.372	0.017	0.019	0.019	0.047	0.211	0.116	-	0.042
Days Of Sales Outstanding, DSO	112	37.8	83.5	-	95.6	114	251	-	69.5	87.1	267	109	-	93.9	65	107	87.6	-	-	-	-	-	-	-	-	-	-	-	-	-
Days Of Inventory Outstanding, DIO	64.4	25	23.4	19.6	60	47.1	104	47.3	188	139	131	154	51.1	971	67.1	131	66.3	170	137	29.9	227	78.5	39.7	43.3	81.7	76.1	77.5	78.4	-	112
Days Of Payables Outstanding, DPO	227	106	238	76.6	176	421	796	148	850	205	317	213	55.6	1.58 K	73.1	143	47.3	141	123	22.9	1.04 K	159	-	19.6	68.2	73	85.4	91.9	-	164
Operating Cycle	177	62.7	107	19.6	156	161	355	47.3	257	226	399	263	51.1	1.06 K	132	239	154	170	137	29.9	227	78.5	39.7	43.3	81.7	76.1	77.5	78.4	-	112
Cash Conversion Cycle	-50.2	-43.6	-131	-57	-19.9	-260	-441	-100	-592	21.2	81.4	50.6	-4.51	-514	59.1	95.4	107	29	13.5	6.99	-814	-80.8	39.7	23.7	13.5	3.13	-7.93	-13.6	-	-52.8
Gross Profit Margin	0.31	0.119	0.29	0.233	0.498	0.42	0.447	-0.559	0.414	0.486	-0.323	0.684	0.045	0.966	-0.293	-0.241	-0.189	0.563	0.563	0.086	0.299	0.447	0.284	0.284	0.384	0.384	0.323	0.323	0.458	0.443
Operating Profit Margin	-0.723	-0.393	-0.315	-0.531	-0.96	-0.355	-0.433	-20.2	-0.578	0.244	-2.37	-1.44	-1.36	-2.8	3.77	-2.16	-1.14	-0.551	-0.551	-0.525	-0.63	-0.683	0.007	0.007	0.152	0.152	0.072	0.072	0.187	0.116
Pretax Profit Margin	-0.822	-0.956	-0.165	-2.1	-1.18	-1.53	-0.843	-20.3	-0.593	-0.17	-4.89	-3.47	-4.44	-2.52	2.53	-0.96	-1.13	-0.526	-0.526	0.592	-3.28	-0.233	0.068	0.068	0.098	0.098	0.027	0.027	0.143	0.031
Net Profit Margin	-0.949	-0.816	-0.324	-2.06	-1.14	-1.82	-0.756	-18.8	-0.206	-0.128	-3.71	-2.67	-4.39	-2.46	2.66	-0.577	-1.15	-0.542	-0.542	0.598	-3.23	-0.205	0.034	0.034	0.069	0.069	0.061	0.061	0.098	0.012
Effective Tax Rate	-0.154	-0.147	-0.665	0.038	0.072	-0.059	0.192	-0.074	-0.652	-0.246	-0.241	-0.041	-0.012	-0.011	0.049	-0.399	-0.015	-0.03	-0.03	0.011	-0.014	0.123	0.5	0.5	0.295	0.295	-1.26	-1.26	0.318	0.622
Return On Assets, ROA	-0.095	-0.105	-0.05	-0.312	-0.136	-0.203	-0.043	-0.73	-0.007	-0.007	-0.124	-0.301	-0.417	-0.188	0.142	-0.025	-0.123	-0.04	-0.051	0.072	-0.077	-0.031	0.007	0.007	0.011	0.015	0.019	0.018	-	0.003
Return On Equity, ROE	-0.257	-1.16	-0.196	-1.29	-0.338	-0.411	-0.077	-1.3	-0.009	-0.009	-0.286	-0.578	-0.589	-0.251	0.201	-0.034	-0.142	-0.044	-0.055	0.09	-0.102	-0.039	0.008	0.013	0.033	0.034	0.026	0.026	-	0.004
Return On Capital Employed, ROCE	-0.184	-0.414	-0.158	-0.266	-0.267	-0.079	-0.041	-1.27	-0.025	0.017	-0.132	-0.245	-0.183	-0.254	0.285	-0.126	-0.14	-0.045	-0.056	-0.079	-0.02	-0.13	0.002	0.003	0.072	0.074	0.03	0.03	-	0.039
Net Income Per Ebt	1.15	0.853	1.96	0.979	0.964	1.19	0.897	0.926	0.348	0.754	0.759	0.771	0.988	0.979	1.05	0.601	1.01	1.03	1.03	1.01	0.986	0.877	0.5	0.5	0.705	0.705	2.26	2.26	0.682	0.378
Ebt Per Ebit	1.14	2.43	0.526	3.95	1.23	4.31	1.95	1	1.02	-0.697	2.06	2.41	3.26	0.899	0.671	0.445	0.992	0.954	0.954	-1.13	5.21	0.342	9.33	9.33	0.645	0.645	0.38	0.38	0.765	0.268
Ebit Per Revenue	-0.723	-0.393	-0.315	-0.531	-0.96	-0.355	-0.433	-20.2	-0.578	0.244	-2.37	-1.44	-1.36	-2.8	3.77	-2.16	-1.14	-0.551	-0.551	-0.525	-0.63	-0.683	0.007	0.007	0.152	0.152	0.072	0.072	0.187	0.116
Debt Ratio	0.444	0.557	0.446	0.497	0.232	0.196	0.111	0.105	0.006	0.073	0.095	0.069	0.164	0.037	0.164	0.103	0.009	0.014	0.017	0.161	0.039	0.048	0.006	0.003	0.0	0.017	0.058	0.061	-	0.043
Debt Equity Ratio	1.2	6.16	1.75	2.05	0.578	0.396	0.198	0.187	0.008	0.096	0.22	0.132	0.232	0.049	0.232	0.139	0.011	0.015	0.019	0.202	0.051	0.061	0.007	0.005	0.0	0.039	0.08	0.087	-	0.062
Long Term Debt To Capitalization	0.032	0.12	0.141	0.201	0.063	0.013	0.07	0.093	0.012	0.017	0.07	0.027	-	-	-	-	0.002	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt To Capitalization	0.545	0.86	0.636	0.672	0.366	0.284	0.165	0.157	0.008	0.088	0.18	0.117	0.188	0.046	0.188	0.122	0.011	0.015	0.019	0.168	0.049	0.057	0.007	0.005	0.0	0.037	0.074	0.08	-	0.059
Interest Coverage	-	-	-3.45	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-98.3	-98.3	-	-	-37.6	1	1	33.1	33.1	5.4	5.4	233	12.8
Cash Flow To Debt Ratio	-0.0	0.0	-0.0	-0.05	-0.063	-0.351	-0.334	-0.094	-1.25	-0.0	-0.0	0.0	-0.0	-0.002	0.0	-0.001	-0.002	-0.013	-0.011	-0.508	-2.33	-2.09	4.46	8.85	-	-	-	-	-	-
Company Equity Multiplier	2.7	11	3.92	4.13	2.49	2.02	1.78	1.78	1.36	1.31	2.31	1.92	1.41	1.33	1.41	1.35	1.15	1.1	1.09	1.26	1.32	1.27	1.23	1.71	3.1	2.27	1.39	1.42	-	1.44
Receivables Turnover	0.803	2.38	1.08	-	0.941	0.788	0.359	-	1.29	1.03	0.337	0.827	-	0.958	1.38	0.837	1.03	-	-	-	-	-	-	-	-	-	-	-	-	-
Payables Turnover	0.397	0.846	0.378	1.17	0.513	0.214	0.113	0.609	0.106	0.439	0.284	0.423	1.62	0.057	1.23	0.627	1.9	0.64	0.731	3.93	0.086	0.565	-	4.59	1.32	1.23	1.05	0.979	-	0.548
Inventory Turn Over	1.4	3.6	3.85	4.59	1.5	1.91	0.863	1.9	0.48	0.646	0.685	0.583	1.76	0.093	1.34	0.685	1.36	0.531	0.659	3.01	0.396	1.15	2.27	2.08	1.1	1.18	1.16	1.15	-	0.807
Fixed Asset Turnover	0.506	0.498	0.661	0.663	0.655	0.652	0.393	0.254	0.61	0.647	0.261	0.923	0.832	1.16	0.468	0.286	0.55	0.406	0.419	0.635	0.127	0.395	4.29	1.72	0.717	0.712	0.586	0.568	-	0.419
Asset Turnover	0.101	0.128	0.154	0.152	0.119	0.112	0.057	0.039	0.032	0.054	0.033	0.113	0.095	0.076	0.053	0.043	0.107	0.074	0.094	0.12	0.024	0.151	0.203	0.215	0.153	0.216	0.304	0.3	-	0.236
Operating Cash Flow Sales Ratio	-0.002	0.0	-0.0	-0.164	-0.123	-0.615	-0.645	-0.254	-0.228	-0.0	-0.0	0.0	-0.0	-0.001	0.0	-0.001	-0.0	-0.002	-0.002	-0.68	-3.77	-0.663	0.13	0.13	-	-	-	-	-	-
Free Cash Flow Operating Cash Flow Ratio	1.1	0.917	1.08	1.01	1	1.04	1.04	1.61	1	0.94	1.67	0.271	1.02	1.02	0.96	1.08	1.04	1.09	1.1	1.35	1.35	1.35	-0.537	-0.537	-	-	-	-	-	-
Cash Flow Coverage Ratios	-0.0	0.0	-0.0	-0.05	-0.063	-0.351	-0.334	-0.094	-1.25	-0.0	-0.0	0.0	-0.0	-0.002	0.0	-0.001	-0.002	-0.013	-0.011	-0.508	-2.33	-2.09	4.46	8.85	-	-	-	-	-	-
Short Term Coverage Ratios	-0.0	0.0	-0.0	-0.057	-0.071	-0.363	-0.54	-0.08	-1.25	-0.0	-0.0	0.0	-0.0	-0.001	0.0	-0.001	-0.003	-0.019	-0.014	-0.519	-2.53	-2.25	4.46	8.85	-	-	-	-	-	-
Capital Expenditure Coverage Ratio	-9.86	12	-12.5	-168	-400	-23.2	-25.5	-1.65	-	-16.8	-1.5	1.37	-49.5	-46.1	25.1	-12.2	-27.5	-10.8	-9.91	-2.82	-2.82	-2.82	0.651	0.651	-	-	-	-	-	-
Dividend Paid And Capex Coverage Ratio	-9.86	12	-12.5	-168	-400	-23.2	-25.5	-1.65	-	-16.8	-1.5	1.37	-49.5	-46.1	25.1	-12.2	-27.5	-10.8	-9.91	-2.82	-2.82	-2.82	0.651	0.651	-	-	-	-	-	-
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Price To Free Cash Flows Ratio, P/FCF	-6 K	68.7 K	-49.1 K	-47.3	-68.4	-14	-20.6	-31.3	-37	-22.7 K	-36.8 K	1.25 M	-24.7 K	-5.65 K	62.2 K	-9.59 K	-40.7 K	-3.66 K	-4.62 K	-8.77	-7.45	-6.86	-424	-488	-1.01 K	-1.04 K	-1.2 K	-1.2 K	-3.17 K	-1.58 K
Price To Operating Cash Flows Ratio, P/OCF	-6.61 K	63 K	-53 K	-47.6	-68.6	-14.6	-21.4	-50.3	-37	-21.4 K	-61.5 K	338 K	-25.2 K	-5.78 K	59.8 K	-10.4 K	-42.2 K	-4 K	-5.09 K	-11.9	-10.1	-9.28	228	262	-	-	-	-	-	-
Price Cash Flow Ratio, P/CF	-6.61 K	63 K	-53 K	-47.6	-68.6	-14.6	-21.4	-50.3	-37	-21.4 K	-61.5 K	338 K	-25.2 K	-5.78 K	59.8 K	-10.4 K	-42.2 K	-4 K	-5.09 K	-11.9	-10.1	-9.28	228	262	-	-	-	-	-	-
Enterprise Value Multiple, EV	-72.6	-33.3	-487	-5.39	-10	-8	-24.6	-8.72	-53	2.51	-2.27	-1.12	-4.9	-0.902	-11.3	-7.63	-7.26	-21.6	-20.2	-16.8	-42.6	-52.9	393	452	499	515	647	649	-	830
Price Fair Value, P/FV	3.59	10.2	3.54	4.89	2.5	2.03	1.41	0.883	0.368	0.473	1.63	1.71	1.44	0.545	0.952	0.771	0.961	0.783	1.07	1.22	1.2	1.18	7.37	12.6	24.2	25.8	11.1	11.2	-	11.3

All numbers in RUB currency

Multiples are an important financial analysis tool for the company Фармсинтез, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios

Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
Aligos Therapeutics ALGS	$ 8.57	-0.81 %	$ 84.7 M	USA
Allakos ALLK	-	-	$ 28.6 M	USA
Alterity Therapeutics Limited ATHE	$ 3.73	1.78 %	$ 8.97 B	Australia
Aptinyx APTX	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	-	-13.39 %	$ 1.45 M	USA
I-Mab IMAB	-	-	$ 866 M	China
AlloVir ALVR	-	4.14 %	$ 49.1 M	USA
BioNTech SE BNTX	$ 99.22	2.61 %	$ 27.2 B	Germany
Burford Capital Limited BUR	$ 4.68	4.23 %	$ 760 M	Britain
Applied Molecular Transport AMTI	-	-	$ 10.1 M	USA
Cabaletta Bio CABA	$ 3.26	1.87 %	$ 328 M	USA
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
Genfit SA GNFT	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
Brainstorm Cell Therapeutics BCLI	-	-2.5 %	$ 5.88 M	USA
Applied Therapeutics APLT	-	-	$ 8.42 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
BeiGene, Ltd. BGNE	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	-	-	$ 546 M	USA
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
Amphastar Pharmaceuticals AMPH	$ 21.41	0.21 %	$ 1 B	USA
Checkpoint Therapeutics CKPT	-	-	$ 169 M	USA
Институт стволовых клеток человека ISKJ	-	-	-	Russia
Adverum Biotechnologies ADVM	-	-	$ 86.2 M	USA
Advaxis ADXS	-	-9.65 %	$ 45.9 M	USA
Clearside Biomedical CLSD	-	-	$ 25.3 M	USA
Aeterna Zentaris AEZS	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	$ 1.53	4.08 %	$ 393 M	USA
Evogene Ltd. EVGN	$ 0.82	0.51 %	$ 27.9 M	Israel
Forte Biosciences FBRX	$ 32.45	6.03 %	$ 420 M	USA
Applied Genetic Technologies Corporation AGTC	-	-	$ 26.5 M	USA
Can-Fite BioPharma Ltd. CANF	$ 3.03	3.7 %	$ 4.99 M	Israel
Aquestive Therapeutics AQST	$ 4.15	-0.95 %	$ 444 M	USA
Arcutis Biotherapeutics ARQT	$ 25.2	4.48 %	$ 3.21 B	USA
Chimerix CMRX	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-	-	$ 401 M	USA
AIkido Pharma AIKI	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	$ 33.28	2.12 %	$ 2.21 B	USA
Galectin Therapeutics GALT	$ 2.45	4.26 %	$ 157 M	USA
Autolus Therapeutics plc AUTL	$ 1.5	2.04 %	$ 399 M	Britain
Aptose Biosciences APTO	-	-45.71 %	$ 1.2 M	Canada
Cidara Therapeutics CDTX	-	-	$ 1.41 B	USA
AVROBIO AVRO	-	1083.1 %	$ 745 M	USA
CNS Pharmaceuticals CNSP	$ 2.61	7.19 %	$ 1.16 M	USA
Ayala Pharmaceuticals AYLA	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	-	-	$ 96.9 B	Britain
Grifols, S.A. GRFS	$ 8.56	2.39 %	$ 6.83 B	Spain

Фармсинтез Financial Ratios 2007-2026 | LIFE

Annual Financial Ratios Фармсинтез

Price Earnings Ratio, P/E

Price Sales Ratio, P/S

Price To Book Ratio, P/B

Price Earnings To Growth Ratio, PEG

Operating Cash Flow Per Share

Free Cash Flow Per Share

Cash Per Share

Payout Ratio

Dividend Yield

Current Ratio

Quick Ratio

Cash Ratio

Days Of Sales Outstanding, DSO

Days Of Inventory Outstanding, DIO

Days Of Payables Outstanding, DPO

Operating Cycle

Cash Conversion Cycle

Gross Profit Margin

Operating Profit Margin

Pretax Profit Margin

Net Profit Margin

Effective Tax Rate

Return On Assets, ROA

Return On Equity, ROE

Return On Capital Employed, ROCE

Net Income Per Ebt

Ebt Per Ebit

Ebit Per Revenue

Debt Ratio

Debt Equity Ratio

Long Term Debt To Capitalization

Total Debt To Capitalization

Interest Coverage

Cash Flow To Debt Ratio

Company Equity Multiplier

Receivables Turnover

Payables Turnover

Inventory Turn Over

Fixed Asset Turnover

Asset Turnover

Operating Cash Flow Sales Ratio

Free Cash Flow Operating Cash Flow Ratio

Cash Flow Coverage Ratios

Short Term Coverage Ratios

Capital Expenditure Coverage Ratio

Dividend Paid And Capex Coverage Ratio

Dividend Payout Ratio

Price To Free Cash Flows Ratio, P/FCF

Price To Operating Cash Flows Ratio, P/OCF

Price Cash Flow Ratio, P/CF

Enterprise Value Multiple, EV

Price Fair Value, P/FV